Seeking Alpha


Send Message
View as an RSS Feed
View biochemist's Comments BY TICKER:
Latest comments  |  Highest rated
  • My 2 Concerns About General Electric's Synchrony Spin-Off [View article]
    Tim - Thank you for your cogent analysis. Unfortunately your article so far has drawn the usual "GE & Immelt suck" commentariat. I truly have sympathy for those, including many GE employees, who sustained great losses in their GE stock-based portfolios. Truly, I do, and I understand the need to express that frustration. However, the venting doesn't change the past. What is GE doing now? Where is it going now? You can all hate GE as much as you want, but Jack Welch built this house of cards. I never, ever see any of the GE-bashers point this out.
    Jul 30, 2014. 08:58 PM | 10 Likes Like |Link to Comment
  • Armour Residential REIT (ARR) declares $0.08/share monthly dividend, 11.1% decrease from prior dividend of $0.09. Forward yield 14.5%. Shares +0.9% AH. (PR[View news story]
    Hi Doc - we like to keep these discussion threads focused on financial matters rather than political ones. There are plenty of other discussion sites for you to go to to express your political opinions.
    Dec 17, 2012. 06:41 PM | 6 Likes Like |Link to Comment
  • PDL BioPharma: Beware The 8% Dividend [View article]
    While I do not disagree with your general point I think that PDLI is the "exception that proves the rule" in this instance. Dave is right that ~70-80% of revenue is about to go away, with an extremely low probability of being able to be replaced. This company is unique in my estimation. I do credit management with attempting to morph PDLI into a biotech BDC of some type in order to continue to survive. It should also be noted that a few years ago management asked shareholders to vote on whether to wrap up activities after Queen et al patent expiry and loss of the revenue or to continue to seek new sources of revenue, so they have responded to shareholders wishes. The shareholders voted to keep the company in existence. I originally bought PDLI in 2009 and sold in mid-2014 after it spiked up to ~$10. I finished well ahead my investment. It was, and is, a unique company and business opportunity, but you have to truly understand this business before you decide to invest.
    Feb 6, 2015. 01:57 PM | 5 Likes Like |Link to Comment
  • Merck: Buyback Plan Not As Impressive As It Appears [View article]
    Good analysis Stone Fox. I view MRK as over-valued at present, which is not the time you want them repurchasing shares. I think a much better use of the $10 billion is to look for and purchase additional targeted acquisitions as they were able to do in 2014 (Cubist, Idenix, OncoEthix). Another way to view the announcement is that MRK senior management doesn't see anything currently available worth acquiring, or that anything worth acquiring is over-priced in their view.
    Mar 29, 2015. 07:05 AM | 4 Likes Like |Link to Comment
  • FDA clears new indication for Bristol-Myers Squibb's Opdivo [View news story]
    This is really great news for lung cancer patients. The PD-1 inhibitor class (and other immunotherapies under development) could very well fundamentally change the way that we treat cancer.
    Mar 4, 2015. 09:39 PM | 4 Likes Like |Link to Comment
  • NYT: Exxon settles $9B New Jersey environmental case for $250M [View news story]
    For those of you claiming that the state of NJ just conducted a shake down on XOM for $250 million dollars, I urge you to read the NY Times story. The litigation was in the penalty stage with the judge determining XOM's final penalty based on the finding of liability. The state requested $8.9 billion in damages. The fact that the state just announced a settlement that is less than 3% of the requested damages is very curious and suggests that there is more to this story than meets the eye.
    Feb 27, 2015. 05:34 PM | 4 Likes Like |Link to Comment
  • Report: Pfizer tentatively offers to acquire AstraZeneca for £60B+ [View news story]
    AZN recently purchased the BMY portion of their joint venture for diabetes. PFE has been trying to move into diabetes drug development and this is one potential way to jump start the effort.
    Apr 20, 2014. 11:11 AM | 4 Likes Like |Link to Comment
  • Total Return BDCs For 2014: Part 2 [View article]
    Hi BDC Buzz - Like all of your other followers I want to thank you for your invaluable service in educating us all about this important sector. After much consideration, study, and DD, including reading and digesting your excellent analyses, I am soon to open small positions in MAIN and TCPC. Long PSEC.
    Feb 1, 2014. 10:02 PM | 4 Likes Like |Link to Comment
  • Update: News On Gilead From The California Technology Assessment Forum [View article]
    We know that all types of patients have serious compliance/adherence issues. In the real world ~50% of patients on daily treatment regimens of various types are not compliant/adherent.
    Dec 19, 2014. 06:07 PM | 3 Likes Like |Link to Comment
  • Will Merck's Acquisition Of Cubist Add Shareholder Value? [View article]
    I view these (Cubist and Idenix) as smart, targeted acquisitions to incrementally provide growth and add to the bottom line. I credit management for identifying promising opportunities and executing on them. This is a MRK that we have not seen before.
    Dec 9, 2014. 06:55 PM | 3 Likes Like |Link to Comment
  • Pfizer cuts profit outlook after Merck deal [View news story]
    SA Editors - PFE's deal is with German-based Merck KGa, not the US Merck
    Nov 17, 2014. 05:59 AM | 3 Likes Like |Link to Comment
  • Best High-Yielding Stocks According To Greenblatt Principles: PDL BioPharma [View article]
    Wow Arie - you respond to 3 commenters who thank you but not to Paulo, Darren, paulsailer, and jenksjr who very rightly pointed out the flaws in your screener based analysis. You, and Louverture for example, do not seem to understand PDLI at all. You cannot place it in a peer group with AMGN. PDLI is an IP holding company. It does no research, it has no products. Lat I checked they had 9 employees. It is not a biotech/biopharma. Once the Queen et al patents expire revenue will begin to drop precipitously unless they are successful in converting themselves into a BDC.

    I was a fairly long-term holder of PDLI, having initially purchased in 2009 until selling it off earlier this year.
    Jul 13, 2014. 01:00 PM | 3 Likes Like |Link to Comment
  • Pfizer: Pfine With Or Without AstraZeneca [View article]
    Do you mean Wyeth? PFE has the entire Wyeth vaccine business still.
    Jun 26, 2014. 06:16 PM | 3 Likes Like |Link to Comment
  • Ashraf Eassa On Seeking Alpha: Millions And Millions Well Served [View article]
    Thanks Chris. I am a bit behind in my SA reading and didn't realize that Ashraf.

    Ashraf - thank you for all of your excellent writing and work. You convinced me to buy INTC and I am currently sitting on a 25% gain (not including dividends).
    May 3, 2014. 04:29 PM | 3 Likes Like |Link to Comment
  • Another Way To Reinvest Dividends [View article]
    Thank you AgAuMoney. I have been digging into this more and I agree with you that opinions on my initial points are considerably mixed and that they tend to fall along political fault lines. I also agree that Glass-Steagall did not have a direct impact on many of the factors that contributed to the recession, as you pointed out, and I agree that "repeal" was limited. The Gramm-Leach-Bliley Act only repealed sections 20 and 32 of Glass-Steagall. Thanks again for the healthy discussion.
    Sep 1, 2012. 07:05 PM | 3 Likes Like |Link to Comment